The need for transparency of clinical evidence for medical devices in Europe

被引:56
|
作者
Fraser, Alan G. [1 ,2 ]
Butchart, Eric G. [3 ]
Szymanski, Piotr [4 ]
Caiani, Enrico G. [5 ,6 ]
Crosby, Scott [7 ]
Kearney, Peter [8 ]
Van de Werf, Frans [2 ]
机构
[1] Cardiff Univ, Sch Med, Univ Wales Hosp, Cardiff, S Glam, Wales
[2] Katholieke Univ Leuven, Dept Cardiovasc Sci, Leuven, Belgium
[3] Univ Hosp Wales, Cardiff, S Glam, Wales
[4] Inst Cardiol, Warsaw, Poland
[5] Politecn Milan, Dept Biomed Engn, Milan, Italy
[6] Politecn Milan, E Hlth, Milan, Italy
[7] Brussels Bar, Brussels, Belgium
[8] Cork Univ Hosp, Dept Cardiol, Cork, Ireland
来源
LANCET | 2018年 / 392卷 / 10146期
关键词
PREMARKET APPROVAL; TRIALS; FOOD; FDA;
D O I
10.1016/S0140-6736(18)31270-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To use medical devices rationally, health-care professionals must base their choices of which devices to recommend for individual patients on an objective appraisal of their safety and clinical efficacy. The evidence submitted by manufacturers when seeking approval of their high-risk devices must be publicly available, including technical performance and premarket clinical studies. Giving physicians access to this information supplements the peer-reviewed scientific literature and might be essential for comparing alternative devices within any class. Interested patients should be encouraged to review the evidence for any device that has been recommended for them. The new EU law on medical devices states that the manufacturer is to prepare a summary of the evidence for any implantable or high-risk device. Defining its content, however, has been delegated to implementing legislation, which is now being considered. From a clinical perspective, it is imperative that all evidence reviewed by notified bodies and regulatory authorities is disclosed-with the exception, if justified, only of technical specifications that are considered confidential or manufacturing details that are protected as intellectual property-and public access to this evidence must be guaranteed by EU law. From ethical and other perspectives, there are no grounds for less clinical evidence being available to health-care professionals about the medical devices that they use than is already available for new pharmaceutical products. Full transparency is needed; without it, informed decisions relating to the use of new medical devices will remain impossible.
引用
收藏
页码:521 / 530
页数:10
相关论文
共 50 条
  • [1] Transparency of clinical evidence for medical devices in Europe reply
    Fraser, Alan G.
    Butchart, Eric G.
    Szymanski, Piotr
    [J]. LANCET, 2019, 393 (10182): : 1693 - 1694
  • [2] Focus on interventional cardiology: the need for quality and transparency of evidence for implantable cardiovascular medical devices
    Crea, Filippo
    [J]. EUROPEAN HEART JOURNAL, 2024, 45 (03) : 147 - 151
  • [3] Trust and transparency in clinical trials of medical devices
    Daniel B. Kramer
    Donald E. Cutlip
    [J]. Nature Reviews Cardiology, 2015, 12 : 503 - 504
  • [5] REGULATORY SCIENCE Trust and transparency in clinical trials of medical devices
    Kramer, Daniel B.
    Cutlip, Donald E.
    [J]. NATURE REVIEWS CARDIOLOGY, 2015, 12 (09) : 503 - 504
  • [6] Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go
    Szymanski, Piotr
    Redberg, Rita
    [J]. EUROPEAN HEART JOURNAL, 2023,
  • [7] Price Transparency For Medical Devices
    Pauly, Mark V.
    Burns, Lawton R.
    [J]. HEALTH AFFAIRS, 2008, 27 (06) : 1544 - 1553
  • [8] Funding of medical education: the need for transparency
    Andreou, Nicholas
    Price, James
    Heymann, Tim
    [J]. CLINICAL MEDICINE, 2014, 14 (04) : 455 - 455
  • [9] Funding of medical education: the need for transparency
    Gray, Denis Pereira
    Harding, Alexander
    [J]. CLINICAL MEDICINE, 2014, 14 (02) : 212 - 213
  • [10] Funding of medical education: the need for transparency
    Dacre, Jane
    Walsh, Kieran
    [J]. CLINICAL MEDICINE, 2013, 13 (06) : 573 - 575